Administration of a nondepleting anti-CD4 monoclonal antibody (W3/25) prevents adjuvant arthritis, even upon rechallenge: parallel administration of a depleting anti-CD8 monoclonal antibody (OX8) does not modify the effect of W3/25.
The aim of this study was to determine the effects of the anti-CD4 monoclonal antibody (mAb) W3/25, found to be nondepleting, on the onset of rat adjuvant arthritis (AA), and, in addition, to ascertain whether depletion of CD8+ cells during the same period could interfere with those effects. Female Wistar rats in which AA had been induced were treated with W3/25 and/or OX8 (anti-rat CD8) mAb during the latency period of arthritis. W3/25 alone or in combination with OX8 prevented the inflammatory process of AA. When the protected groups were rechallenged with a second dose of Mycobacterium butyricum no arthritis was observed. Protected and nonprotected arthritic animals developed the same anti-mycobacteria antibody levels as the arthritic control group. This study indicates that a nondepleting anti-CD4 mAb can prevent AA, while CD8+ lymphocytes do not appear relevant for the development of AA and do not seem to have a regulatory role for CD4+ cells.
Pelegrí
C
C
Unit of Physiology, Faculty of Pharmacy, University of Barcelona, Spain.
Paz Morante
M
M
Castellote
C
C
Castell
M
M
Franch
A
A
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000276:immunology / Q000517:prevention & control*; D015704:CD4 Antigens / Q000502:physiology*; D016516:CD4-CD8 Ratio; D016827:CD8 Antigens / Q000502:physiology*; D005260:Female; D051379:Mice; D009161:Mycobacterium / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D016827:CD8 Antigens